New vaccine aims to outsmart ovarian cancer recurrence
NCT ID NCT06639074
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to target a protein (FRα) found on many ovarian tumor cells. Half of the 78 participants will receive the vaccine, and half will receive a placebo, to see if the vaccine improves recurrence-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dendritic cell vaccine targeting folate receptor alpha (FRαDCs)
- What this could lead to
- If it works, this vaccine could help delay or prevent cancer recurrence in people with advanced ovarian cancer, offering a new way to keep the disease under control.
- What could go wrong
- This is a phase II trial with only 78 participants, so results are still early. The vaccine may not work better than placebo, and side effects from immune activation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Email: •••••@•••••
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Email: •••••@•••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Scientists probe hidden clues to immunotherapy success in endometrial cancer
- Engineered immune cells take aim at Hard-to-Treat cancers
- Exercise and diet counseling may help cancer patients finish chemo
- New drug aimed at folate receptor shows promise for tough endometrial cancer